Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

all risk groups in international prognostic index
diagnosis of aggressive T-cell-lymphoma, confirmed by an excisional biopsy of a lymph node or by sufficiently extensive biopsy of an extranodal involvment, if there is no lymph node involvment.
these lymphomas comprise: peripheral T-cell lymphoma PTCL-NOS Lennert´s lymphoma T-zone lymphoma angioimmunoblastic T-cell-lymphoma
Performance status: ECOG (Eastern Cooperative Oncology Group Score) 0-3(Karnofsky index 40-100%)
written consent of the patient
Declaration of center participation

Already initiated lymphoma therapy(exept for the prephase treatment specified for this study)
Serious accompanying disorder or impaired organ function
bone marrow involvement\>25%
Known hypersensitivity to medications to be used
Know HIV-positivity
Active hepatitis infection, active CMV infection, prior florid tuberculosis
floride systemic infections
suspicion that patient compliance will be poor
Simultaneous participation in any the study protocol
prior chemo-or radiotherapy for malignancy
other concomitant malignant disease
Pregnancy or lactation period

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma